OncoMatch/Clinical Trials/NCT05557604
Sbrt±sTad for Unfavorable iNtermediate rIsk/High Risk Prostate caNcer
Is NCT05557604 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Decapeptyl for prostate cancer.
Treatment: Decapeptyl — This is a prospective, open, randomized phase II trial.
Check if I qualifyExtracted eligibility criteria
Cancer type
Prostate Cancer
Disease stage
Required: Stage N0M0
N0M0 at staging with choline or (preferably) PSMA PET-CT
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: surgery
Previous local treatment of the prostate with surgery (radical prostatectomy or cryotherapy)
Cannot have received: radiation therapy
Previous radiotherapy to the pelvis
Cannot have received: chemotherapy
Exception: within past 5 years
Previous chemotherapy for malignancy in past 5 years
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify